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Oxygen-derived free radicals are highly reactive 
chemical species containing an unpaired electron. 
They are capable of reacting with lipids, proteins 
and nucleic acids and are thought to have a major 
role in the pathogenesis of a variety of diseases 
including atherosclerosis, diabetes and cancer. 
Antioxidants protect and limit free radical damage 
and it is the balance between free radical activity 
and antioxidant mechanisms that determine the 
potential for tissue damage [1,2]. Oxidative stress 
exists when there are either low levels of these 
antioxidants or increased production of reactive 
oxygen species (ROS). 
In chronic renal failure patients there is a high 
incidence of premature cardiovascular disease [3] 
which despite advances in renal therapy, remains 
one of the leading causes of death in patients with 
end-stage renal failure. This can be partly explained 
by the increased prevalence of the major 
cardiovascular risk factors, including diabetes, 
hypercholesterolaemia and hypertension. However 
despite this, a significant proportion of the increased 
cardiovascular risk remains unexplained. 
Oxidative stress may play a role in atherogenesis as 
it is thought that oxidation of polyunsaturated fatty 
acids in plasma lipids, particularly in low density 
lipoproteins (LDL), leads to modification of lysine 
residues on apolipoprtoein B. The resulting 
modified LDL particle can be taken up by the         
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macrophage scavenger receptor in the arterial wall 
[4,5], resulting in the formation of foam cells, a key 
early step in the initiation of the atherosclerotic 
plaque. 
This paper reviews the evidence for oxidative stress 
in patients with chronic renal failure, notably in 
those requiring maintainence haemodialysis. In 
addition the important therapeutic options are 
discussed. 
 
Evidence for ros production 
 
Many studies have shown that chronic renal failure 
(CRF) patients exhibit an increased production of 
ROS [6]. This process is exacerbated by 
haemodialysis (HD) [7,8]. There are a number of 
potential sources of increased radical production in 
CRF. 
 
Advanced glycation endproducts (AGE) and 
hypertrigyceridaemia 
 
Diabetes and chronic renal failure share similar 
disease mechanisms. Diabetes is known to be 
associated with glycated proteins undergoing 
reactions leading to increased radical production 
[9,10]. Advanced glycation endproducts are also 
increased in patients with CRF and may participate 
in oxidative reactions [11]. The accumulation of 
AGEs in uraemic plasma proteins is not correlated 
with increased glucose. This can be explained by 
increased plasma concentrations of small reactive 
carbonyl precursors of AGEs resulting from 
increased oxidation of carbohydrates and lipids [12].   
 
Hypertriglyceridaemia in diabetics can increase 
monocyte free radical production [13,14]. CRF 
patients frequently have hypertriglyceridaemia 
which may contribute to production of ROS. 
 
HD membrane bioincompatibility 
 
There is evidence that exposure to particular HD 
membranes can cause an inflammatory reaction and 
bioincompatibility. In one study 37 patients with 
acute renal failure using a polymethylacrylate 
(PMA) membrane were compared with 35 using a 
cuprophane membrane [15]. 62% of patients using 
the PMA membrane recovered renal function 
independent of dialysis compared with 37% in the 
cuprophane group and median days of dialysis was 
5 compared with 17. A further report comparing 
cuprophane membranes with a noncellulosic 
membrane (polyacrylonitrile AN 69, PAN) revealed 
a reduction of complement C3a and leukotriene B4 
in the PAN group [16]. HD membrane-induced 
activation of phagocytes and the production of ROS 
has been shown to increase using 
chemiluminescence [17,18]. 
This indicates that membrane incompatibility 
activates complement and neutrophils which in turn 
triggers the release of ROS. Bioincompatibility 
represents an important source of ROS formation: 
namely the superoxide anion and its metabolites 
(hydrogen peroxide and the hydroxyl radical) 
[19,20] and hydroperoxides released enzymatically 
from arachidonic acid [21,22]. 
In addition, it has been suggested that the 
superoxide generated during HD can react with 
bicarbonate to form the toxic carbonate and formate 
radicals which are capable of causing lipid 




Iron supplementation is often indicated for the 
treatment of anaemia in CRF patients. The oxidative 
metabolism of LDL is related with intracellular iron 
metabolism [24] and there is increased lipid 
peroxidation in red blood cells in patients on HD 
treated with iron [25]. 
 
Depletion of antioxidants 
 
Despite the above mechanisms for the generation of 
ROS, LDL oxidation would be minimised if it were 
adequately protected by antioxidants.  
Antioxidant enzymes such as superoxide dismutase, 
catalase and glutathione peroxidase are preventive 
antioxidants, because they eliminate species 
involved in the inititation of free radical chain 
reactions. There is some controversy in the literature 
as to whether activity of these enzymes is increased 





Vitamin C is considered to be the first line of 
defence against ROS. Vitamin C has been shown to 
scavenge aqueous superoxide and hydroxyl radicals 
and act as a chain-breaking antioxidant in lipid 
peroxidation. Vitamin E will not be affected until 
vitamin C is depleted [31].  
There is a low basal plasma concentration of 
vitamin C in HD patients, which further decreases 
during an HD session [27,32]. During HD plasma 
vitamin C drops to approximately 50% of the basal 
value and takes 44 hour to return to initial levels 
[33]. Therefore there is an increased need of vitamin 
C supplementation in HD patients to avoid critically 




Vitamin E is a generic term to describe at least eight 
compounds that exhibit the biological activity of 
alpha-tocopherol. Vitamin E deficiency may be 
exacerbated by a deficiency of selenium (a 
necessary cofactor for glutathione peroxidase). ROS 
generated during lipid peroxidation extract 
hydrogen ions from vitamin E. Following 
interaction with ROS, vitamin E can be regenerated 
using ubiquinol, reduced glutathione or vitamin C. 
Vitamin E concentration in erythrocytes and 
mononuclear cells are low in HD patients despite 




Reduced glutathione (GSH) is a tripeptide (structure 
L-glutamyl-L-cysteinelglycine) with major anti-
oxidant properties. It protects tissues from 
xenobiotic oxidants and reactive electrophiles that 
result in free radical injury. In all mammalian cells 
the concentration of GSH is high (millimolar range) 
despite variation in the biological half-life; less than 
one hour in kidney compared to several days in 
erythrocytes.  
GSH concentration closely correlates with the 
degree of renal failure [39]. There is evidence of 
low levels of whole blood and erythrocyte levels of 
glutathione in haemodialysis and peritoneal dialysis 
patients [40]. Therefore, oxidative stress may occur 
as a result of the GSH deficiency in CRF. 
 




Vitamin C has complex interactions with iron 
metabolism, leading to enhanced mobilization from 
storage sites. Vitamin C acts as a reducing agent, 
allowing iron release from ferritin [41] and 
haemosiderin [42] pools. As a result it has been 
reported that vitamin C supplementation may 
alleviate resistance to erythropoietin that sometimes 
occurs in iron overloaded patients [43]. However 
care with dosage is important as supplementation 
with 3 grams per week or more of vitamin C can 





Thus far , three clinical trials have studied the effect 
of vitamin E supplements on coronary heart disease 
and have shown evidence of reduced morbidity [45-
47]. The enhanced oxidative susceptibility of small 
dense LDL appears to be related to reduced content 
of vitamin E or a reduced vitamin E to 
polyunsaturated fatty acid ratio [48].  
Fish oil has been thought beneficial to many clinical 
studies with suggested actions on alteration in 
cytokine and eicosanoid production and decreased 
platelet aggregation [49]. Fish oil supplements 
(15g/day) reduce circulating vitamin E levels via 
increased vitamin E utilization and decreased 
gastrointestinal absorption. Fish oils are also highly 
enriched in unsaturated fatty acids. Thus, greater 
quantities of vitamin E may be needed to protect 
LDL from oxidation in these patients. Utilization of 
fish oil and vitamin E improves the plasma lipid and 
lipoprotein profile in HD patients [50] and the 
combination may prove a means of reducing 
atherosclerosis-related morbidity and mortality in 
HD patients. 
Oral supplementation with vitamin E has been 
reported to improve the haematocrit [36] and 
reduction in dosage of erythropoietin needed to 
maintain a stable haemoglobin in HD patients [51]. 
Intracellular vitamin E in HD patients are lower than 
in healthy subjects and erythrocyte vitamin E 
concentrations are further decreased with 
erythropoietin treatment. This may be explained by 
a direct effect from erythropoietin per se or most 
probably due to iron supplementation administered 
to the patients [25].  
Similarly lipid peroxidation in both platelets and 
peripheral blood mononuclear cells is increased in 
patients on HD; vitamin E supplementation results 
both in improved platelet function and altered 
immune response [37,52,53]. 
A vitamin-E-modified cellulose (CL-E) haemo-
dialysis membrane has been reported to reduce 
lipoperoxidation in plasma and red blood cells. It is 
suggested that CL-E membranes reduce the effect of 
bioincompatability on the generation of ROS and 




Administration of reduced glutathione appears to 
ameliorate the intraerythrocyte oxidative defence. 
One study suggests glutathione increases red blood 
cell survival and reduces the dose of erythropoetin 
in the treatment of anaemia in CRF [55]. Increased 
oxidised glutathione in CRF may react with 
haemoglobin and cause protein aggregation in 
erythrocytes. These alterations cause haemolysis 
and could play a role in the pathogenesis of anaemia 




Carotenoids are also chain breaking antioxidants but 
have yet to prove of value in supplementation. Less 
than 10% of these compounds can be metabolised to 
retinal and function as vitamin A. Vitamin A 
concentrations are significantly raised in HD 
patients due to reduced renal excretion [57]. 
Vitamin A has been shown to be at least as effective 
as vitamin E as an antioxidant in vitro studies. 
However this has not been proven clinically. 
Vitamin A has been given to CRF patients but in 
combination with vitamins C and E with 




The generation of ROS and depletion of key chain-
breaking and enzymatic antioxidants present in HD 
patients produces oxidative stress and subsequent 
increase in the development of atherosclerosis. 
Supplementation with antioxidants improves 
markers of oxidative stress. Although the number of 
studies are small, there is evidence of a beneficial 
effect of antioxidants on clinical outcome. An 
antioxidant cocktail should therefore be considered 
for clinical trials in patients with CRF who require 
HD. 
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